NuLife Sciences Inc. Stock Price - NULF

Best deals to access real time data!
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN Company Description
Nulife Sciences Inc. (QB) NULF Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0 +0% 0.66 0.66 0.66 0.66 0.66 14:36:05
Bid Price Ask Price Spread Spread % News
0.445 0.66 0.215 32.58% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 1,023 2.27k 0.26 - 1.50
Last Trade Time Type Quantity Stock Price Currency
14:35:59 1,023 $0.66 USD

Nulife Sciences Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 20.52M 31.09M $ -559.27k - -36.68 6.99M
Short Interest Short % of Out Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
1.05k 0.00% $ - 0.00% - -

more financials information »

Nulife Sciences Inc. (QB) News

Latest NULF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NULF Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.660.660.440.000004k1k0-
1 Month0.
3 Months0.640.70.40.0000022k2k0.023.13%
6 Months0.610.40.0000025k3k0.0610.00%
1 Year0.25651.50.25650.0000087k6k0.4035157.31%
3 Years0.25651.50.25650.0000087k6k0.4035157.31%
5 Years0.25651.50.25650.0000087k6k0.4035157.31%

Nulife Sciences Inc. (QB) Description

NuLife Sciences is a biomedical company focused on medical research and technology that has the potential to address significant unmet medical needs in applications including transplantation/regenerative medicine/cell therapy/organ and tissue transplants. Through its wholly-owned subsidiary NuLife BioMed, it is currently working on advancing human organ transplant technology based upon a patent protected and unique proprietary method ("NuLife Technique") that could potentially eliminate the need for an organ or tissue match and the necessity for anti-rejection drugs. With a massive need and market for organ transplants, and over 123K candidates waiting for an organ in the U.S. alone, NuLife's versatile technique is suitable for a variety of clinical indications. The Company has completed discovery phase for its technique, and is now entering a Preclinical phase involving animal studies on its pathway to commercialization. For more information please visit

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.